Jake Jorgovan

JANUARY 30, 2024

His career highlights include igniting US reimbursement pathways for Prescription Digital Therapeutics (PDT), pioneering value-based collaboration between payers and manufacturers, and introducing groundbreaking biotech and healthtech solutions. His role involves fostering alliances within the pharmaceutical and biotech industries.

Biopharma 130

Biopharma Life science Biotech Biopharmaceuticals 130

Frost & Sullivan

AUGUST 6, 2023

San Antonio, TX — 7 th Aug, 2023 — Frost & Sullivan recently researched the Asia-Pacific biotechnology contract research organization industry and, based on its findings, recognizes Avance Clinical with the 2023 Customer Value Leadership Award. In addition, the attractive 43.5%

Biotechnology 52

Biotechnology Biotech Contract research organization Biopharmaceuticals 52

Frost & Sullivan

MARCH 28, 2025

Download our full analysis on the top 6 growth opportunities in pharma and biotech. Between 2017 and 2023, the US RLT market saw over 550% growth in total venture capital deals. The key to success lies in strategic partnerships, robust supply chain management, and continuous investment in groundbreaking therapeutics.

Biotech 52

Biotech Biotechnology Strategic partnership Insurance 52

Frost & Sullivan

OCTOBER 11, 2024

San Antonio, TX — 14 th October 2024 — Frost & Sullivan recently conducted an in-depth analysis of the biotech contract research organization (CRO) industry and based on its findings, has awarded Novotech the 2024 Global Company of the Year Award.

Biotech 52

Biotech Contract research organization Strategic partnership Collaboration 52

Frost & Sullivan

MARCH 5, 2025

Investment Outlook: Biohybrid technologies will see strong adoption in biotech, environmental science, and smart wearables. Regional Insights: APAC: South Korean startups like PAENE Biotech are pioneering mitochondrial-targeted therapies. Leverage strategic partnerships in clean energy, biotech, and smart infrastructure.

Biotech 52

Biotech Energy Fintech Construction 52

Frost & Sullivan

FEBRUARY 20, 2025

Investment Outlook: Expect biotech & pharma companies to increase R&D partnerships in nanoencapsulation and targeted drug delivery. Regional Insights : India: The DPDP Act (2023) is pushing companies to enhance identity security and Zero Trust models. Explore the latest innovations and strategies driving growth.

Biotech 52

Biotech Energy Banking Government 52